

Silvia Busquets Rius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854666/publications.pdf>

Version: 2024-02-01

156
papers

8,512
citations

30070

54
h-index

51608

86
g-index

159
all docs

159
docs citations

159
times ranked

8151
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of Synergy Between β^2 -Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1953-1959.	2.0	1
2	Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. <i>Journal of Cellular Physiology</i> , 2020, 235, 526-537.	4.1	10
3	Exercise Reduces the Resumption of Tumor Growth and Proteolytic Pathways in the Skeletal Muscle of Mice Following Chemotherapy. <i>Cancers</i> , 2020, 12, 3466.	3.7	20
4	Win 55,212-2, atenolol and subdiaphragmatic vagotomy prevent acceleration of gastric emptying induced by cachexia via Yoshida-AH-130 cells in rats. <i>European Journal of Pharmacology</i> , 2020, 877, 173087.	3.5	4
5	The animal cachexia score (ACASCO). <i>Animal Models and Experimental Medicine</i> , 2019, 2, 201-209.	3.3	9
6	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. <i>Journal of Molecular Biology</i> , 2019, 431, 2674-2686.	4.2	69
7	Therapeutic strategies against cancer cachexia. <i>European Journal of Translational Myology</i> , 2019, 29, 7960.	1.7	44
8	Mediators of cachexia in cancer patients. <i>Nutrition</i> , 2019, 66, 11-15.	2.4	50
9	Cancer cachexia, a clinical challenge. <i>Current Opinion in Oncology</i> , 2019, 31, 286-290.	2.4	18
10	Inter-tissue communication in cancer cachexia. <i>Nature Reviews Endocrinology</i> , 2019, 15, 9-20.	9.6	191
11	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. <i>Biochimie</i> , 2018, 149, 79-91.	2.6	39
12	Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats. <i>Biochemistry and Biophysics Reports</i> , 2018, 14, 26-34.	1.3	1
13	Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes. <i>Frontiers in Physiology</i> , 2018, 9, 1819.	2.8	2
14	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. <i>JCSM Rapid Communications</i> , 2018, 1, 1-15.	1.6	3
15	Omega-3 and omega-3/curcumin-enriched fruit juices decrease tumour growth and reduce muscle wasting in tumour-bearing mice. <i>JCSM Rapid Communications</i> , 2018, 1, 1-10.	1.6	5
16	Novel targeted therapies for cancer cachexia. <i>Biochemical Journal</i> , 2017, 474, 2663-2678.	3.7	55
17	Validation of the CACHexia SCORe (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. <i>Frontiers in Physiology</i> , 2017, 8, 92.	2.8	46
18	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. <i>Frontiers in Physiology</i> , 2017, 8, 184.	2.8	17

#	ARTICLE	IF	CITATIONS
19	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20
20	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
21	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <sc>II</sc> receptor inhibition and Î² agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
22	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology, 2016, 54, 20-27.	5.0	58
23	Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 84-94.	7.3	38
24	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56
25	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43
26	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
27	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78
28	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44
29	A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation-contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
30	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
31	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
32	Recent Developments in Treatment of Cachexia. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 259-273.	0.6	1
33	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
34	The cachexia score (CASCO) as a tool for staging cachectic cancer patients.. Journal of Clinical Oncology, 2014, 32, e20700-e20700.	1.6	0
35	Mechanisms and treatment of cancer cachexia. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S19-S24.	2.6	44
36	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83

#	ARTICLE	IF	CITATIONS
37	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. <i>International Journal of Oncology</i> , 2013, 43, 886-894.	3.3	79
38	Central Melanin-Concentrating Hormone Influences Liver and Adipose Metabolism Via Specific Hypothalamic Nuclei and Efferent Autonomic/JNK1 Pathways. <i>Gastroenterology</i> , 2013, 144, 636-649.e6.	1.3	79
39	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. <i>Journal of Lipid Research</i> , 2013, 54, 3045-3051.	4.2	17
40	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. <i>Oncology Letters</i> , 2012, 3, 185-189.	1.8	31
41	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 37-43.	7.3	115
42	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. <i>E-SPEN Journal</i> , 2012, 7, e135-e138.	0.5	3
43	Theophylline is able to partially revert cachexia in tumour-bearing rats. <i>Nutrition and Metabolism</i> , 2012, 9, 76.	3.0	18
44	L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012, 31, 889-895.	5.0	37
45	Counteracting Inflammation: A Promising Therapy in Cachexia. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 253-262.	0.4	59
46	Are there any benefits of exercise training in cancer cachexia?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 73-76.	7.3	102
47	Myostatin: more than just a regulator of muscle mass. <i>Drug Discovery Today</i> , 2012, 17, 702-709.	6.4	105
48	Nutrition and cachexia. , 2012, , 185-194.		0
49	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. <i>International Journal of Molecular Medicine</i> , 2011, 27, 15-24.	4.0	70
50	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 731-735.	1.8	16
51	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. <i>Obesity</i> , 2011, 19, 362-369.	3.0	80
52	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. <i>Clinical Nutrition</i> , 2011, 30, 33-37.	5.0	10
53	Anti-inflammatory therapies in cancer cachexia. <i>European Journal of Pharmacology</i> , 2011, 668, S81-S86.	3.5	63
54	Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 57-62.	7.3	22

#	ARTICLE	IF	CITATIONS
55	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 87-93.	7.3	138
56	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 95-104.	7.3	72
57	Interleukin-15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. <i>Lipids</i> , 2011, 46, 1033-1042.	1.7	25
58	Effects of formoterol on protein metabolism in myotubes during hyperthermia. <i>Muscle and Nerve</i> , 2011, 43, 268-273.	2.2	5
59	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16
60	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. <i>Oncology Reports</i> , 2011, 25, 189-93.	2.6	33
61	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. <i>Clinical Nutrition</i> , 2010, 29, 733-737.	5.0	27
62	Patterns of gene expression in muscle and fat in tumor-bearing rats: Effects of CRF2R agonist on cachexia. <i>Muscle and Nerve</i> , 2010, 42, 936-949.	2.2	5
63	Optimal management of cancer anorexia–cachexia syndrome. <i>Cancer Management and Research</i> , 2010, 2, 27.	1.9	57
64	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. <i>Antioxidants and Redox Signaling</i> , 2010, 12, 365-380.	5.4	71
65	Therapeutic strategies in cachexia: Current and future directions. <i>Drugs of the Future</i> , 2010, 35, 41.	0.1	1
66	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. <i>Drug Discovery Today</i> , 2009, 14, 208-213.	6.4	61
67	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. <i>FEBS Letters</i> , 2009, 583, 350-356.	2.8	33
68	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
69	The role of cytokines in cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 263-268.	1.3	162
70	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. <i>International Journal of Molecular Medicine</i> , 2009, 24, 453-8.	4.0	23
71	PPAR γ mediates IL15 metabolic actions in myotubes: Effects of hyperthermia. <i>International Journal of Molecular Medicine</i> , 2009, 24, .	4.0	1
72	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. <i>Anticancer Research</i> , 2009, 29, 1315-7.	1.1	9

#	ARTICLE	IF	CITATIONS
73	PPARdelta mediates IL15 metabolic actions in myotubes: effects of hyperthermia. International Journal of Molecular Medicine, 2009, 24, 63-8.	4.0	5
74	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
75	Effects of IL15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
76	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
77	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
78	Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncology Reports, 2008, 19, 253-6.	2.6	5
79	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of 125 I-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43
80	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
81	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1028-1036.	2.4	9
82	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
83	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
84	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
85	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
86	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58
87	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29
88	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
89	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
90	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79

#	ARTICLE	IF	CITATIONS
91	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. <i>FEBS Letters</i> , 2006, 580, 691-696.	2.8	26
92	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006, 1760, 253-258.	2.4	16
93	Effects of interleukin-15 on lipid oxidation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 37-42.	2.4	50
94	BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. <i>Oncology Reports</i> , 2006, 15, 1425.	2.6	2
95	Cytokines as Mediators and Targets for Cancer Cachexia. <i>Cancer Treatment and Research</i> , 2006, 130, 199-217.	0.5	50
96	IGF-1 is downregulated in experimental cancer cachexia. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R674-R683.	1.8	149
97	BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. <i>Oncology Reports</i> , 2006, 15, 1425-8.	2.6	6
98	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. <i>Nutrition</i> , 2005, 21, 977-985.	2.4	86
99	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. <i>Medicinal Research Reviews</i> , 2005, 25, 49-65.	10.5	162
100	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. <i>ChemInform</i> , 2005, 36, no.	0.0	1
101	Impact on fatty acid metabolism and differential localization of FATP1 and FAT/CD36 proteins delivered in cultured human muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 288, C1264-C1272.	4.6	67
102	Effects of Water Stress on Respiration in Soybean Leaves. <i>Plant Physiology</i> , 2005, 139, 466-473.	4.8	245
103	Interleukin-15 decreases proteolysis in skeletal muscle: A direct effect. <i>International Journal of Molecular Medicine</i> , 2005, 16, 471.	4.0	24
104	Interleukin-15 decreases lipid intestinal absorption. <i>International Journal of Molecular Medicine</i> , 2005, 15, 963.	4.0	2
105	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1084-1104.	2.8	144
106	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1609-1619.	2.8	38
107	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 2036-2046.	2.8	89
108	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. <i>FEBS Letters</i> , 2005, 579, 717-722.	2.8	48

#	ARTICLE	IF	CITATIONS
109	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
110	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
111	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
112	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817.	4.0	4
113	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
114	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
115	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
116	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95
117	The systemic inflammatory response is involved in the regulation of K ⁺ channel expression in brain via TNF- α -dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26
118	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
119	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma. International Journal of Molecular Medicine, 2004, 14, 719-23.	4.0	5
120	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
121	Impaired voltage-gated K ⁺ channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
122	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
123	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102
124	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
125	Changes in Mitochondrial Electron Partitioning in Response to Herbicides Inhibiting Branched-Chain Amino Acid Biosynthesis in Soybean. Plant Physiology, 2003, 133, 1351-1359.	4.8	58
126	Title is missing!. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	20

#	ARTICLE	IF	CITATIONS
127	Cytokines in the pathogenesis of cancer cachexia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003, 6, 401-406.	2.5	114
128	Sepsis induces DNA fragmentation in rat skeletal muscle. <i>European Cytokine Network</i> , 2003, 14, 256-9.	2.0	12
129	TNF- α is involved in activating DNA fragmentation in skeletal muscle. <i>British Journal of Cancer</i> , 2002, 86, 1012-1016.	6.4	71
130	The role of uncoupling proteins in pathophysiological states. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 1145-1152.	2.1	90
131	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002, 1570, 33-37.	2.4	87
132	TNF- α modulates cytokine and cytokine receptors in C2C12 myotubes. <i>Cancer Letters</i> , 2002, 175, 181-185.	7.2	33
133	Tumor necrosis factor- α exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1542, 66-72.	4.1	55
134	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. <i>Journal of Cellular Physiology</i> , 2002, 191, 283-289.	4.1	38
135	Muscle ubiquitin mRNA levels in patients with end-stage renal disease on maintenance hemodialysis. <i>Journal of Nephrology</i> , 2002, 15, 552-7.	2.0	11
136	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 17-24.	2.4	146
137	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. <i>Cancer Letters</i> , 2001, 167, 33-38.	7.2	88
138	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor- α ?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2001, 1499, 249-256.	4.1	23
139	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. <i>FEBS Letters</i> , 2001, 505, 255-258.	2.8	29
140	Metabolic interrelationships between liver and skeletal muscle in pathological states. <i>Life Sciences</i> , 2001, 69, 1345-1361.	4.3	21
141	Increased muscle ubiquitin mRNA levels in gastric cancer patients. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 280, R1518-R1523.	1.8	123
142	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. <i>Journal of Cellular Physiology</i> , 2000, 184, 380-384.	4.1	60
143	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. <i>Journal of Nutritional Biochemistry</i> , 2000, 11, 431-435.	4.2	31
144	Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. <i>British Journal of Cancer</i> , 2000, 83, 526-531.	6.4	160

#	ARTICLE	IF	CITATIONS
145	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
146	Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochimica Et Biophysica Acta - General Subjects, 2000, 1475, 5-9.	2.4	31
147	Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2000, 157, 99-103.	7.2	4
148	Mechanism for the increased skeletal muscle protein degradation in the obese zucker rat. Journal of Nutritional Biochemistry, 1999, 10, 244-248.	4.2	16
149	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
150	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64
151	In the rat, tumor necrosis factor $\hat{\alpha}$ administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
152	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
153	The Increased Skeletal Muscle Protein Turnover of the Streptozotocin Diabetic Rat Is Associated with High Concentrations of Branched-Chain Amino Acids. Biochemical and Molecular Medicine, 1997, 61, 87-94.	1.4	44
154	The AP-1/NF- $\hat{\kappa}$ B double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 0, , .	3.3	12
155	Effects of the PPAR $\hat{\alpha}$ agonist GW1929 on muscle wasting in tumour-bearing mice. Oncology Reports, 0, , .	2.6	4
156	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. Insciences Journal, 0, , 1-17.	0.7	9